Novo Nordisk A/S’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less ...

Novo Nordisk A/S (NYSE:NVO ... NVO is on track for its biggest daily and weekly percentage losses on record, as well as a fourth-straight loss. Shares now carry a 20% deficit for 2024, and ...

Thursday's gains put Novo Nordisk shares at a record high of more than $108. The stock gained more than 50% last year when booming demand for its diabetes and weight-loss drugs Ozempic and Wegovy ...

Novo Nordisk ... % from what Novo Nordisk is expected to report a year ago. Over the past month, the estimate has changed -2.1%. With an impressive externally audited track record, our proprietary ...

Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future ...

COPENHAGEN, Dec 5 (Reuters) - Danish drug maker Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% from January of ...

(Bloomberg) -- Novo Nordisk A/S’s shares fell by the most on record after a failed attempt to leapfrog rival Eli Lilly & Co. in the red-hot market for obesity drugs. Novo’s experimental ...

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ...